Here are five things to know:
1. The financing was led by HealthpointCapital.
2. The financing also included existing investors Smith & Nephew and TriVentures.
3. The proceeds will facilitate continued market adoption, clinical study programs and entry into the emerging markets.
4. OrthoSpace’s flagship product is InSpace, a disruptive technology for treating severe rotator cuff tears. The technology addresses a large growing market segment with limited treatment options for the continuum-of-care for rotator cuff injury.
5. The terms of the agreement were not disclosed.
“With five years of clinical experience and over 5,000 procedures completed, we have developed a loyal following among surgeons in Europe and Israel,” said Assaf Dekel, MD, OrthoSpace’s co-founder and medical director.
More articles on orthopedic devices:
47 orthopedic & spine devices receive FDA 510(k) clearance in April
Implanet gets FDA clearance for new JAZZ rod sizes—5 things to know
LDR COO sells 1.2k shares in $49k transaction: 5 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
